Health Care : Current Reviews

Kim Brøsen

Publications

• Review Article
  The Monoamine Oxidase Inhibitor Isocarboxazid is a Relevant Treatment Option in Treatment-Resistant Depression-Experience-Based Strategies in Danish Psychiatry
  Author(s): Jens Knud Larsen, Lene Krogh-Nielsen and Kim BrøsenJens Knud Larsen, Lene Krogh-Nielsen and Kim Brøsen
  
  The clinical use of monoamine oxidase inhibitors (MAOIs) like isocarboxazid nowadays is most often seen with treatment resistant depression, which is in accordance with the registered indication of the National Health Service of Denmark. The clinical use, however, early became restricted and today it covers only a minority of the market for antidepressants. The aim of the present paper is to give a short overview of the clinical efficacy, to review mechanisms of action and metabolism of MAOIs, and to discuss how the side effects and interactions with these drugs may be avoided. A number of clinical trials have documented that MAOIs are effective antidepressants in major depression, including in patients with melancholic syndrome. In Denmark the combined use of nortriptyline with isocarboxazid as add-on treatment for more than 30 years has proved to be safe and efficie.. View More»
  DOI: 10.4172/2375-4273.1000168

  Abstract PDF